Interesting ImagesPseudoprogression on 68Ga–Prostate-Specific Membrane Antigen-11 PET/CT in a Treated GlioblastomaGupta, Manoj DRM, FEBNM∗; Choudhury, Partha Sarathi DNB∗; Gairola, Munish MD†; Premsagar, Ishwar Chandra MCH‡; Rao, Sriram Avinash MD§Author Information From the Departments of ∗Nuclear Medicine †Radiotherapy ‡Neuro and Spine Oncology Services §Radiology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. Received for publication December 21, 2019; revision accepted April 13, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Manoj Gupta, DRM, FEBNM, Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, New Delhi, India, 110085. E-mail: firstname.lastname@example.org. Clinical Nuclear Medicine: August 2020 - Volume 45 - Issue 8 - p 621-622 doi: 10.1097/RLU.0000000000003121 Buy Metrics Abstract After standard treatment of glioblastoma, pseudoprogression versus true progression is a clinical challenge. Indeed, to differentiate these 2 on contrast MRI (cMRI) is problematic. In recent time, 68Ga–prostate-specific membrane antigen-11 (68Ga-PSMA) PET/CT has been suggested to have high accuracy in glioblastoma recurrence. We present a case of a 40-year-old man with right frontotemporal glioblastoma underwent surgery and radiotherapy. One month posttreatment cMRI showed a new enhancing lesion in the right hippocampal region, which was also positive on 68Ga-PSMA-11 PET/CT. On follow-up with conservative management, both cMRI and 68Ga-PSMA-11 PET/CT showed regression in new lesion, hence suggest pseudoprogression. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.